UPM Raflatac has launched a range of pharmaceutical labelling materials which support compliance with the Falsified Medicines Directive (2011/62/EU) regarding packaging for prescription drugs and high-risk, over-the-counter medicines. The Directive requires that pharmaceutical product packaging should carry a unique serial number to identify and authenticate individual products. Furthermore the products should be sealed in such a way as to make it obvious if anyone has tampered with it.
In response, UPM Raflatac has developed two new adhesives – RP 62 EU and RP 62 EUL – which are combined with transparent filmic label faces to make any tampering evident with no need to change existing graphic design.
UPM Raflatac also used the PharmaPack show in February earlier this month to show RP 31 Purus, an adhesive that minimizes migration risk in medical, pharmaceutical and healthcare applications.
Another solution – RP Cryo – is an adhesive that can withstand direct, long-term immersion in liquid nitrogen in temperatures as low as -196 °C. UPM claims that it offers good printability with thermal transfer for automated sample management to reduce the possibility of human error when marking by hand.
Leave a Reply